Navigation Links
Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
Date:7/13/2011

; and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections.  The open-label study builds on Chimerix's extensive experience working with over 150 clinicians at over 80 leading institutions in the United States, Canada, Europe, and Israel who have sought CMX001 under EINDs for the treatment of immunocompromised patients.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, including the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine.  Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV and HBV infections, including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, influenza, malaria an
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Chimerix Joins International Network of Organizations to Cure Malaria
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
9. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
10. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
11. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... , More sensitive than ... Linear quantitation of mRNA targets , over a 106-fold range ... as 500 fg total RNA 1/20th of a single cell! , Fast, ... 15 min , , ...
... Fluorescence activated cell sorting (FACS) is a , ... individual cells using fluorescent probes that bind specifically to ... commonly used to collect , cells of a given ... , Figure 1.Linear Amplification from 1-1000 Cells. , ...
... Remove >90% of mammalian RNA from , ... Simple procedure takes less than 2 hours , ... with , MICROB Express Bacterial mRNA Purification Kit ... bacterial RNA isolated from host cells , ...
Cached Biology Technology:HIGH SENSITIVITY qRT-PCR 2HIGH SENSITIVITY qRT-PCR 3HIGH SENSITIVITY qRT-PCR 4HIGH SENSITIVITY qRT-PCR 5Cells-to-cDNA II Using FACS Sorted Cells 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 3Bacterial RNA Isolation From Infected Eukaryotic Hosts 4Bacterial RNA Isolation From Infected Eukaryotic Hosts 5Bacterial RNA Isolation From Infected Eukaryotic Hosts 6
(Date:4/17/2014)... ideas about domestication derive from Charles Darwin, whose ... animal-breeding practices during the 19th century, a period ... , It is from Darwin that we inherit ... animals from wild species and total human control ... management in this industrial setting has been applied ...
(Date:4/16/2014)... State University researchers have identified a new syndrome called ... and muscle mass with obesity. , "It used to ... better your bones would be because the bones were ... Professor of Nutrition at Florida State. "But, that,s only ...
(Date:4/16/2014)... Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has just received ... in the amount of nearly US$600,000. The 5-year grant is ... called RNases and to explore their biomedical potential in the ... , "Receiving a grant at this level is ...
Breaking Biology News(10 mins):The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... U.S. west coast is among the richest ecosystems in the ... a great diversity of marine life. Like coastal regions in ... new study led by scientists at the University of California, ... impacts are highest on marine predators such as whales, seals, ...
... better electronics developed during the last decade, as ... energy storage, and clean water. However, exposure to ... and the environment. As a resource for ... Center for Sustainable Nanotechnology (VTSuN) has joined the ...
... University studying the cause of a rare childhood disease ... new findings may provide clues to understanding more common ... tools to treat them. In today,s online edition ... Hart and Jiali Li in the Department of Cell ...
Cached Biology News:Study maps human impacts on top ocean predators along US west coast 2Study maps human impacts on top ocean predators along US west coast 3Nanomaterials database improved to help consumers, scientists track products 2Nanomaterials database improved to help consumers, scientists track products 3Nanomaterials database improved to help consumers, scientists track products 4Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 2Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 3
...
... inhibition of RNase A-type ribonucleases Product Description: ... nonhuman origin that binds noncovalently and inactivates ... B, and C). It does not interfere ... or CL3. QIAGEN RNase Inhibitor inhibits greater ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: